DLBCL
Conference Coverage
On second thought, lenalidomide does improve DLBCL outcomes
LUGANO, SWITZERLAND – Adding lenalidomide to R-CHOP reduced the risk of diffuse large B-cell lymphoma progression or death by 34% in the ECOG-...
Conference Coverage
R2-CHOP doesn’t improve survival in DLBCL
LUGANO, SWITZERLAND – The ROBUST trial is the latest in a long line of studies that failed to show improvement in outcomes with the addition of a...
From the Journals
CNS-directed therapy appears more effective for synDLBCL
Two-year survival rates were superior among patients who received CNS-intensive therapy.
From the Journals
Dasatinib shows promise as a control agent for CAR T cells
The tyrosine kinase inhibitor dasatinib was found to transiently inhibit CAR T-cell function in a preclinical study, suggesting applicability as...
Conference Coverage
No benefit with rituximab after first CR in DLBCL
AMSTERDAM – Rituximab maintenance was no better than observation for patients in first complete remission after induction chemotherapy with R-CHOP...
From the Journals
Radiation bridging with axi-cel appears safe in DLBCL
At final follow-up, in a case series of 12 patients with relapsed/refractory DLBCL, the best objective response rate was 81.8%, with complete...
From the Journals
Polatuzumab vedotin combo shows promise in DLBCL
Polatuzumab vedotin plus rituximab or obinutuzumab, in addition to cyclophosphamide, doxorubicin, and prednisone, showed manageable safety and...
From the Journals
Influenza vaccination status in DLBCL poorly documented
Routine outpatient vaccination screening and strategies for sharing and linking patient vaccination status could improve vaccination documentation...